SCHEMBL4537720

SCHEMBL4537720

CCc1ccc(-c2c(-c3ccccc3F)oc3ncnc(OC(C)CCCCC(=O)OC(C)(C)C)c23)cc1

nearest known ligand 0.34

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
AURKA O14965 6/20 0.34
MERTK Q12866 2/20 0.33
AURKB Q96GD4 1/20 0.31
EGFR P00533 2/20 0.31
KDR P35968 1/20 0.31
TEK Q02763 1/20 0.31
AXL P30530 1/20 0.30
TYRO3 Q06418 1/20 0.30
CHEK1 O14757 1/20 0.30
MCL1 Q07820 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4530370 1.00 AURKA (0.34) AURKAMERTKAURKBEGFRKDR
SCHEMBL4531369 0.91 TEK (0.39) AURKAMERTKKDRTEKCHEK1
SCHEMBL4525220 0.90 AURKA (0.37) AURKAMERTKAURKBEGFRKDR
SCHEMBL4533516 0.90 AURKA (0.37) AURKAMERTKAURKBEGFRKDR
SCHEMBL4531667 0.90 AURKA (0.37) AURKAMERTKAURKBEGFRKDR
SCHEMBL12409712 0.87 AURKA (0.35) AURKAMERTKAURKBEGFRKDR
SCHEMBL4530700 0.85 AURKA (0.34) AURKAMERTKAURKBEGFRKDR
SCHEMBL12409629 0.84 MCL1 (0.32) AURKAAURKBMCL1
SCHEMBL12409630 0.82 AURKA (0.39) AURKAMERTKAURKBEGFRCHEK1
SCHEMBL12409708 0.82 TEK (0.39) AURKAMERTKKDRTEKCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966217-B1 NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER IP GMBH (DE) 2013-05-08 EP disclosed
US-8183246-B2 Acyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-05-22 US disclosed
US-8183246-B2 Acyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-05-22 US disclosed
US-8183246-B2 Acyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-05-22 US disclosed
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-12-24 US disclosed
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-12-24 US disclosed
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-12-24 US disclosed
WO-2008131858-A2 USE OF ACYCLICALLY SUBSTITUTED FUROPYRIMIDINE DERIVATIVES FOR TREATING PULMONARY ARTERIAL HYPERTONIA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-11-06 WO disclosed
WO-2007079862-A1 NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof DPYD, PNPO, TPMT AURKA 2909/4885MERTK 1999/4885AURKB 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.